Fig. 1
Study flow chart. N number of participants, CT cycle threshold, SOT sotrovimab, TIX/CIL tixagevimab plus cilgavimab, NMV/r nirmatrelvir plus ritonavir.
Fig. 1 | Scientific Reports
Study flow chart. N number of participants, CT cycle threshold, SOT sotrovimab, TIX/CIL tixagevimab plus cilgavimab, NMV/r nirmatrelvir plus ritonavir.
